New $150M VC fund to target Quebec life sciences

There’s a new venture capital pipeline on the ground for Quebec’s life sciences sector.

Montreal-based Teralys Capital has put $65 million into TVM LifeScience Ventures VII, a new $150-million fund focused on early stagedrug development and other life sciences activities. Other investors inthe fund are Eli Lilly Canada, Business Development Bank of Canada,Fondaction, and Advantus Capital Management.

As part of the deal surrounding the fund, Eli Lilly will set up adivision of its drug development unit in Montreal that will be calledChorus Canada.

Today’s announcement comes just days after Teralys also invested in anew Celtic House VenturePartners media communications fund worth $105million.

Would you recommend this article?

Share

Thanks for taking the time to let us know what you think of this article!
We'd love to hear your opinion about this or any other story you read in our publication. Click this link to send me a note →

Jim Love, Chief Content Officer, IT World Canada

Related Tech News

Get ITBusiness Delivered

Our experienced team of journalists brings you engaging content targeted to IT professionals and line-of-business executives delivered directly to your inbox.